Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Spesolimab in Perianal Fistulising Crohn's Disease
NCT04362254Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of spesolimab in Perianal fistulizing Crohn's disease (PFCD), sponsored by Boehringer Ingelheim. Started May 2020; status: terminated.
02
Drugs
spesolimab
03
Conditions
Perianal fistulizing Crohn's disease (PFCD)
Beyond the preview
Go deeper on NCT04362254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362254.